RxDoctor Payments DataLook up a doctor →

Katelyn Siano

Family · Provo, UTNPI 1780209668

Payments from drug & device makers

$28,703in general payments, 2019–2025

Across 541 payments — averaging $53.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$18K
  • Medtronic$2K
  • Amgen$934
  • Boehringer Ingelheim$756
  • Lilly USA, LLC$739
  • Dexcom, Inc.$683
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$3,16411%
  • Speaking & faculty fees$11,18639%
  • Travel & lodging$3,78613%
  • Food & beverage$10,53537%
  • Education$320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,703 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$70,861
Medicare patients
191
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide244$377,741
JardianceEmpagliflozin145$203,813
TrulicityDulaglutide116$155,665
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog55$119,732
FarxigaDapagliflozin Propanediol87$106,116
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog93$93,357
ForteoTeriparatide16$79,705
Tresiba Flextouch U-200Insulin Degludec48$70,034
Synjardy XrEmpagliflozin/Metformin Hcl58$61,459
TymlosAbaloparatide21$56,068
TradjentaLinagliptin46$55,543
Soliqua 100-33Insulin Glargine/Lixisenatide27$51,576
JanuviaSitagliptin Phosphate32$40,404
OzempicSemaglutide30$39,698
Xigduo XrDapaglifloz Propaned/Metformin31$38,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Baqsimi$739$631,110426 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$756$320,814249 claims
AstraZenecaFarxiga$326$106,11687 claims
Radius Health, Inc.Tymlos$313$56,06821 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$18,489$55,98738 claims
MerckJanuvia$38$40,40432 claims
Novo NordiskOzempic$217$39,69830 claims
BayerKerendia$541$14,33813 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$2,126219 claims
AbbVieSynthroid$330$1,97424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.

Other family in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →